Lilly’s Dosing Scheme For Donanemab In Alzheimer’s And Treatment Cost Effectiveness
Executive Summary
Firm’s aggressive approach to amyloid plaque removal means a shorter duration of treatment and potentially lower costs.
You may also be interested in...
Medicare And Alzheimer’s Drugs: Pressure To Relax Coverage Restrictions Rising Wtih Donanemab Data
Lilly's donanemab may be the second amyloid-targeting drug for Alzheimer’s headed toward a traditional US Food and Drug Administration approval this year, setting up a showdown with Medicare over its coverage with evidence development requirements.
ICER’s Leqembi Assessment Inches Higher, Still Sees Eisai Price As Too High
The drug pricing watchdog said in its revised report that Alzheimer’s therapy Leqembi (lecanemab) meets cost-effectiveness thresholds at $8,900-$21,500, below Eisai/Biogen’s $26,500 list price.
Medicaid ‘Price Verification’ Audit Proposal Aims To Promote Cell, Gene Therapy Rebate Concessions
CMS proposed rule impact may be ‘modest’ but is framed as ensuring patient access to cutting edge treatments by helping to control Medicaid spending. Biden administration initiative also aims to address misclassification of brand drugs, duplicative 340B discounts, and PBM spread pricing.